SOLARANSESolara Active Pharma Sciences Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 6 Feb, 2026 · 13:47 IST

Solara Active Pharma Q3 FY26 Net Loss at Rs 17.43 Cr

Going ConcernExceptional ItemPat NegativeRevenue DeclineEbitda Margin CompressionResults View source PDFExplain this filing

SOLARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-12.3%Reaction day
₹529.00
prior close
₹520.50
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.8%-11.5% vs market
Pharmaceuticals peers, median of 159sector-0.6%-11.7% vs sector

On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-5.1
10m
-4.7
15m
-3.6
30m
-5.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-12.3-0.8-11.5-0.6-11.7
Next day
-9.6+1.8-11.4+1.2-10.8
2d
-7.8+2.8-10.6+1.8-9.6
3d
-8.0+2.3-10.3+1.3-9.3
4d
-9.6+1.8-11.4+0.7-10.3
5d
-5.7+0.3-6.0+0.0-5.8
1w
-9.2+0.5-9.7-0.2-9.0
15d
-13.1-2.5-10.6-2.3-10.8
1m
-12.3-6.3-6.0-4.4-8.0
2m
-11.2-8.0-3.2-7.2-3.9
3m
-3.6+8.3-11.8+2.7-6.3
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Solara Active Pharma Q3 FY26 revenue at Rs 349 Cr, up 16% YoY. But company swung to net loss of Rs 17.43 Cr in Q3 and Rs 17.01 Cr for 9M FY26 (vs Rs 8.09 Cr profit YoY). Includes Rs 6.75 Cr exceptional charge for gratuity under new labour codes. 9M revenue down 3% to Rs 982 Cr. Going concern note flags accumulated losses of Rs 329.64 Cr and current liabilities exceeding assets by Rs 92.44 Cr. Plans Rs 134.99 Cr rights issue final call.

Likely market impact

Negative: net loss, going concern flag, accumulated losses of Rs 329.64 Cr. Watch rights issue final call.